Anorexia Nervosa - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 2 PAGES: 39

More Info
									Anorexia Nervosa – Pipeline Review, H2 2011




                Anorexia Nervosa - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1457IDB

                                                                                          Publication Date: October 2011




Anorexia Nervosa – Pipeline Review, H2 2011                                                                      GMDHC1457IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Anorexia Nervosa – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 4
Introduction .............................................................................................................................................................................................................. 5
      Global Markets Direct Report Coverage ............................................................................................................................................................. 5
Anorexia Nervosa Overview ..................................................................................................................................................................................... 6
Therapeutics Development ....................................................................................................................................................................................... 7
      An Overview of Pipeline Products for Anorexia Nervosa .................................................................................................................................... 7
Anorexia Nervosa Therapeutics under Development by Companies ......................................................................................................................... 9
Anorexia Nervosa Therapeutics under Investigation by Universities/Institutes .........................................................................................................10
Late Stage Products ................................................................................................................................................................................................12
      Comparative Analysis .......................................................................................................................................................................................12
Mid Clinical Stage Products .....................................................................................................................................................................................13
      Comparative Analysis .......................................................................................................................................................................................13
Early Clinical Stage Products ..................................................................................................................................................................................14
      Comparative Analysis .......................................................................................................................................................................................14
Anorexia Nervosa Therapeutics - Products under Development by Companies.......................................................................................................15
Anorexia Nervosa Therapeutics - Products under Investigation by Universities/Institutes ........................................................................................16
Companies Involved in Anorexia Nervosa Therapeutics Development ....................................................................................................................17
      Daiichi Sankyo Company, Ltd ...........................................................................................................................................................................17
Anorexia Nervosa - Therapeutics Assessment ........................................................................................................................................................18
      Assessment by Monotherapy Products .............................................................................................................................................................18
      Assessment by Combination Products ..............................................................................................................................................................19
      Assessment by Route of Administration ............................................................................................................................................................20
      Assessment by Molecule Type ..........................................................................................................................................................................22
Drug Profiles ...........................................................................................................................................................................................................24
      SUN11031 - Drug Profile...................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24
            Mechanism of Action...................................................................................................................................................................................24
            R&D Progress .............................................................................................................................................................................................24
      Kanglaite - Drug Profile .....................................................................................................................................................................................25
            Product Description ....................................................................................................................................................................................25
            Mechanism of Action...................................................................................................................................................................................25
            R&D Progress .............................................................................................................................................................................................25
      Seroquel - Drug Profile ......................................................................................................................................................................................26
            Product Description ....................................................................................................................................................................................26
            Mechanism of Action...................................................................................................................................................................................26
            R&D Progress .............................................................................................................................................................................................26
      Aripiprazole - Drug Profile .................................................................................................................................................................................27
            Product Description ....................................................................................................................................................................................27
            Mechanism of Action...................................................................................................................................................................................27
            R&D Progress .............................................................................................................................................................................................27
      Oxytocin - Drug Profile ......................................................................................................................................................................................28
            Product Description ....................................................................................................................................................................................28
            Mechanism of Action...................................................................................................................................................................................28
            R&D Progress ....................................................................................................
								
To top